B
BLRX
vs
T
Tel Aviv 355
Over the past 12 months, BLRX has underperformed Tel Aviv 355, delivering a return of -35% compared to the Tel Aviv 355's +59% growth.
Stocks Performance
BLRX vs Tel Aviv 355
Performance Gap
BLRX vs Tel Aviv 355
Performance By Year
BLRX vs Tel Aviv 355
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BioLine RX Ltd
Glance View
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.